

Additional file 2. Baseline pulmonary microbiological findings in patients with isolated pulmonary *Candida spp.* colonization (cohort 1).

	Antifungal therapy (n=102)	No antifungal therapy (n=220)	p-value
<i>Candida spp.</i>, n (%)			
<i>albicans</i>	71 (69.6%)	180 (81.8%)	0.02
<i>glabrata</i>	18 (17.6%)	37 (16.8%)	0.874
<i>tropicalis</i>	11 (10.8%)	15 (6.8%)	0.271
<i>krusei</i>	6 (5.9%)	1 (0.5%)	0.005
Others ¹	8 (7.8%)	9 (4.1%)	0.184
Co-Infection with <i>Aspergillus</i> , n (%)	2 (2%)	3 (1.4%)	0.654
Any pulmonary bacterial finding, n (%)	25 (25%)	94 (43%)	0.002
Gram positive	6 (5.9%)	17 (7.7%)	0.647
Gram negative	21 (20.6%)	84 (38.2%)	0.002
<i>E. coli</i>	5 (4.9%)	21 (9.5%)	0.19
<i>Pseudomonas aeruginosa</i>	5 (4.9%)	14 (6.4%)	0.8
<i>Klebsiella pneumonia</i>	3 (2.9%)	9 (4.1%)	0.759
<i>Enterobacter species</i>	3 (2.9%)	9 (4.1%)	0.759
Others ²	5 (4.9%)	31 (14.1%)	0.014
<i>multi drug resistant pathogens</i>	2 (2%)	5 (2.3%)	1

¹ *Candida famata*, *kefyr*, *lipolytica*, *lusitaniae* and *parapsilosis*.

² *Stenotrophomonas*, *Proteus mirabilis*, *Serratia marcescens*, *Citrobacter koseri*, *Actinobacter baumannii*, *Klebsiella ocytoca*, *Proteus vulgaris*, *Citrobacter freundii*, *Morganella morganii*.